Trials / Terminated
TerminatedNCT00239655
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension is offered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0812 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-12-01
- Completion
- 2006-01-01
- First posted
- 2005-10-17
- Last updated
- 2016-08-01
Source: ClinicalTrials.gov record NCT00239655. Inclusion in this directory is not an endorsement.